Berenberg has initiated coverage of BioNTech (BNTX) and Moderna (MRNA), citing their leadership positions in mRNA medicine.

Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says mRNA will ...

Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...

Turin Art week may be focused around Artissima, Italy’s oldest art fair, but there's must-see exhibitions to found across the ...

This Will Not End Well” is the incredible retrospective that the Neue Nationalgalerie dedicates to one of the most important ...

Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to ...

API technology startup Kong Inc. said today it has closed on a bumper $175 million late-stage round of funding, bringing its ...

Lidia Fonseca, CIO of Pfizer, heads data solutions and products across Pfizer and spearheads digitizing processes such as drug discovery and clinical development. She also works to streamline digital ...

Shares are trading lower in Europe after gaining in Asia after U.S. stocks recovered somewhat from last week's swoon. Oil ...

Key Takeaways The S&P 500 added 0.4% on Tuesday, Nov. 19, as investors digested a strong report from a major retailer and ...

Other drug manufacturers declined in the days following the nomination. Pfizer and Moderna have declined 6.9% and 6.2% ...

The attack came just days after President Biden gave Ukraine permission to use the weapons to strike targets inside Russia. By Marc Santora and Eric Schmitt The envoy, Amos Hochstein, said an ...